Self‐Propelled Magnetic Nanorobots Alleviating Tumor Hypoxia for Targeted Drug Delivery
Source abstract
Abstract
Abstract The biological barrier and hypoxic microenvironment of tumor tissues remain major challenges in clinical therapeutics. Self‐propelled nanorobots have emerged as a promising strategy to overcome these limitations, enabling deep drug penetration and amelioration of tumor hypoxia. In this study, an asymmetric badminton‐shaped magnetic nanorobot platform is developed featuring a microporous tail structure. These nanorobots are functionalized with lactate dehydrogenase, catalase, and triptolide through electrostatic adsorption. The cascade reaction of these two enzymes provides a driving force for magnetic nanorobots, while further improving the hypoxic microenvironment of tumor tissues by degrading lactic acid metabolites. Furthermore, surface modification with nucleic acid aptamers enhanced the active targeting capability of the nanorobots. In vitro simulation experiments and biological validation comprehensively evaluated the deep drug delivery capabilities and tumor treatment efficacy of the resulting nanorobots. Collectively, this study provides important implications for ongoing deeper tumor treatments.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Micro and Nano Robotics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Spin‐X Institute School of Chemistry and Chemical Engineering South China University of Technology Guangzhou 511442 China
Breast Center Department of General Surgery Nanfang Hospital Southern Medical University Guangzhou 510515 China
School of Materials Shenzhen Campus of Sun Yat‐sen University Shenzhen 518107 China
Funding
Key Technologies Research and Development Program · National Natural Science Foundation of China
References (31)
Show source-provided references
1. 10.3322/caac.2149210.3322/caac.21492 ↗
2. 10.3389/fendo.2019.0057310.3389/fendo.2019.00573 ↗
3. 10.1159/00050867510.1159/000508675 ↗
4. 10.1016/j.bbrc.2021.12.08910.1016/j.bbrc.2021.12.089 ↗
5. 10.1002/med.2133810.1002/med.21338 ↗
6. 10.1038/nm.440910.1038/nm.4409 ↗
7. 10.1021/acs.chemrev.8b0062610.1021/acs.chemrev.8b00626 ↗
8. 10.1039/C7CS00471K10.1039/C7CS00471K ↗
9. 10.1002/adma.20190177810.1002/adma.201901778 ↗
10. 10.1021/am507680u10.1021/am507680u ↗
11. 10.1002/smll.20140101310.1002/smll.201401013 ↗
12. 10.1038/s12276-021-00640-910.1038/s12276-021-00640-9 ↗
13. 10.1186/s13046-021-02128-w10.1186/s13046-021-02128-w ↗
14. 10.1016/j.cub.2020.06.08110.1016/j.cub.2020.06.081 ↗
15. 10.1021/acsnano.7b0721410.1021/acsnano.7b07214 ↗
16. 10.1126/sciadv.abn388310.1126/sciadv.abn3883 ↗
17. 10.1016/j.jconrel.2022.09.00310.1016/j.jconrel.2022.09.003 ↗
18. 10.1021/acsami.1c0885710.1021/acsami.1c08857 ↗
19. 10.1016/j.semcancer.2024.06.00310.1016/j.semcancer.2024.06.003 ↗
20. 10.1093/nsr/nwx06210.1093/nsr/nwx062 ↗
21. 10.1016/j.jconrel.2010.02.02410.1016/j.jconrel.2010.02.024 ↗
22. 10.1002/adhm.20230421210.1002/adhm.202304212 ↗
23. 10.1021/acs.chemrev.0c0123410.1021/acs.chemrev.0c01234 ↗
24. 10.1002/advs.20200220310.1002/advs.202002203 ↗
25. 10.1002/adfm.20170610010.1002/adfm.201706100 ↗
26. 10.1016/j.nantod.2024.10233710.1016/j.nantod.2024.102337 ↗
27. 10.1038/nmat125110.1038/nmat1251 ↗
28. 10.1002/adma.20130273710.1002/adma.201302737 ↗
29. 10.1021/jacs.6b1262210.1021/jacs.6b12622 ↗
30. 10.1021/jacs.2c1221910.1021/jacs.2c12219 ↗
31. 10.1038/srep1567510.1038/srep15675 ↗